LeVaGyn
ActiveSummary
LeVaGyn has been active since 2021 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €100 and a net result of €113,184. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 5% of 20,453 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
02-03
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Back to profitnet €113,184
Net result €113,184 after 2 loss-making years.
09-07
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
04-07
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-12
Financial
Weakest financial yearnet -€51,466
Net result drops to -€51,466, the lowest in the series; recovery starts the following year.
31-12
Financial
Liquidity more than 70 timescurrent ratio 328.85
Current ratio from 4.65 to 328.85; short-term debt falls from €28,983 to €151.
03-07
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
31-12
Financial
Equity above €100,000equity €105,473 ▲73.9%
A profit in every financial year since 2021 builds equity to €105,473.
28-07
NBB filing
Annual accounts filed
financial year 2021 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.